Alx Oncology Holdings (ALXO) Other Gross PP&E Adjustments (2019 - 2026)
Alx Oncology Holdings recorded quarterly Other Gross PP&E Adjustments of $1.9 million in Q1 2026, up 11.64% quarter-over-quarter from $1.7 million in Q4 2025, and up 57.09% year-over-year from $1.2 million in Q1 2025.
Alx Oncology Holdings' Other Gross PP&E Adjustments history runs 8 years deep, the most recent figure standing at $1.9 million for Q1 2026.
- In Q1 2026, Other Gross PP&E Adjustments rose 57.09% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $1.9 million (up 57.09% YoY), while the FY2025 annual figure was $1.7 million, up 69.65% from the prior year.
- Other Gross PP&E Adjustments came in at $1.9 million for Q1 2026 at Alx Oncology Holdings, up from $1.7 million in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of $3.5 million in Q3 2023 to a low of -$4.7 million in Q2 2022.
- A 5-year average of $176294.1 and a median of $769000.0 in 2024 frame the typical range for Other Gross PP&E Adjustments.
- Across the five-year window, Other Gross PP&E Adjustments slumped 18792.0% in 2022 and jumped 391.29% in 2025, its largest moves.
- Alx Oncology Holdings' Other Gross PP&E Adjustments stood at -$2.2 million in 2022, then surged by 211.85% to $2.4 million in 2023, then sank by 59.52% to $982000.0 in 2024, then jumped by 69.65% to $1.7 million in 2025, then gained by 11.64% to $1.9 million in 2026.
- According to Business Quant data, Other Gross PP&E Adjustments over the past three periods registered $1.9 million, $1.7 million, and $1.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Alx Oncology Holdings | 189.80 Mn | 49.48 Mn | - | 1.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.86 Mn |
| Mar 31, 2026 | 1.86 Mn |
| Dec 31, 2025 | 1.67 Mn |
| Dec 31, 2025 | 1.67 Mn |
| Sep 30, 2025 | 1.43 Mn |
| Sep 30, 2025 | 1.43 Mn |
| Jun 30, 2025 | 991,000.00 |
| Jun 30, 2025 | 991,000.00 |
| Mar 31, 2025 | 1.18 Mn |
| Mar 31, 2025 | 1.18 Mn |
| Dec 31, 2024 | 982,000.00 |
| Dec 31, 2024 | 982,000.00 |
| Sep 30, 2024 | 769,000.00 |
| Sep 30, 2024 | 769,000.00 |
| Jun 30, 2024 | 541,000.00 |
| Jun 30, 2024 | 541,000.00 |
| Mar 31, 2024 | 241,000.00 |
| Mar 31, 2024 | 241,000.00 |
| Dec 31, 2023 | 2.43 Mn |
| Dec 31, 2023 | 2.43 Mn |
| Sep 30, 2023 | 3.50 Mn |
| Sep 30, 2023 | 3.50 Mn |
| Jun 30, 2023 | -587,000.00 |
| Jun 30, 2023 | -587,000.00 |
| Mar 31, 2023 | -1.68 Mn |
| Mar 31, 2023 | -1.68 Mn |
| Dec 31, 2022 | -2.17 Mn |
| Dec 31, 2022 | -2.17 Mn |
| Sep 30, 2022 | -3.84 Mn |
| Sep 30, 2022 | -3.84 Mn |
| Jun 30, 2022 | -4.72 Mn |
| Jun 30, 2022 | -4.72 Mn |
| Mar 31, 2022 | 404,000.00 |
| Mar 31, 2022 | 404,000.00 |
| Dec 31, 2021 | -576,000.00 |
| Dec 31, 2021 | -576,000.00 |
| Sep 30, 2021 | -578,000.00 |
| Sep 30, 2021 | -578,000.00 |
| Jun 30, 2021 | -25,000.00 |
| Jun 30, 2021 | -25,000.00 |
| Mar 31, 2021 | -230,000.00 |
| Mar 31, 2021 | -230,000.00 |
| Dec 31, 2020 | -223,000.00 |
| Dec 31, 2020 | -223,000.00 |
| Sep 30, 2020 | -203,000.00 |
| Sep 30, 2020 | -203,000.00 |
| Jun 30, 2020 | -2.09 Mn |
| Jun 30, 2020 | -2.09 Mn |
| Dec 31, 2019 | 2.19 Mn |
| Dec 31, 2019 | 2.19 Mn |